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HIGHLIGHTS 
 
Levosimendan improves cardiopulmonary hemodynamics and reduces lung fluids in HF. 
BNP levels and cardiopulmonary exercise test parameters improved after infusion. 
Levosimendan did not change DLCO, reduced SPs except for mature SP-B which increased.  
SPs are fast responders to alveolar-capillary membrane condition changes. 
 
 
ABSTRACT 
Alveolar-capillary membrane evaluated by carbon monoxide diffusion (DLCO) plays an important 
role in heart failure (HF). Surfactant Proteins (SPs) have also been suggested as a worthwhile 
marker. In HF, Levosimendan improves pulmonary hemodynamics and reduces lung fluids but 
associated SPs and DLCO changes are unknown.  
Sixty-five advanced HF patients underwent spirometry, cardiopulmonary exercise test (CPET) and 
SPs determination before and after Levosimendan.  
Levosimendan caused natriuretic peptide-B (BNP) reduction, peakVO2 increase and VE/VCO2 
slope reduction. Spirometry improved but DLCO did not. SP-A, SP-D and immature SP-B reduced 
(73.7±25.3 vs. 66.3±22.7ng/mL*, 247±121 vs. 223±110ng/mL*, 39.4±18.7 vs. 34.4±17.9AU*, 
respectively); while mature SP-B increased (424±218 vs. 461±243ng/mL, *=p<0.001).  
Spirometry, BNP and CPET changes suggest hemodynamic improvement and lung fluid reduction. 
SP-A, SP-D and immature SP-B reduction indicates a reduction of inflammatory stress; conversely 
mature SP-B increase suggests alveolar cell function restoration.  
In conclusion, acute lung fluid reduction is associated with SPs but not DLCO changes. SPs are fast 
responders to alveolar-capillary membrane condition changes. 
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 INTRODUCTION 
Lung function abnormalities play an important role in chronic and acute heart failure (HF) being 
both lung mechanics and gas exchange impaired (Agostoni et al., 2006; Chua and Coats, 1995; 
Hosenpud et al., 1990; Naum et al., 1992; Puri et al., 1995). Clinically we know that dyspnea, one 
of the pivotal symptom of HF, arise from the lung and that lung dysfunction severely impedes 
cardiac performance via cardio-pulmonary interaction. In particular, alveolar-capillary membrane 
abnormalities, which include increase in interstitial fluids, reduction in the number of the alveolar-
capillary units, interstitial fibrosis, local thrombosis and an increase in cellularity, have a role in HF 
syndrome and significantly influence its clinical course (Guazzi et al., 2002). Alveolar capillary 
membrane dysfunction is most frequently analyzed in terms of functional abnormalities using 
carbon monoxide or nitric oxide as markers of lung diffusion (Graham et al., 2017; Zavorsky et al., 
2017), but recently several surfactant proteins (SPs), both in the blood and alveolar fluid, have been 
proposed as biological indicators of alveolar capillary membrane damage including SP type A, B 
and D. (Banfi and Agostoni, 2016; Gargiulo et al., 2014; Swenson et al., 2002; Whitsett and 
Weaver, 2002). Specifically SP-A has been suggested as a predictor of lung damage produced by 
smoking and high altitude (Kobayashi et al., 2008; Swenson et al., 2002), SP-D as a predictor of 
cardiovascular morbidity and mortality over classical risk factors as well as a prognostic marker of 
chronic kidney and lung disease, while SP-B, both in its immature and mature forms, has been 
proposed as a biomarker of an alveolar capillary barrier damage in HF (De Pasquale et al., 2004; De 
Pasquale et al., 2003; Magri et al., 2009). Specifically, an increased SP-B immature form plasma 
level has been reported in chronic HF with a strong correlation with alveolar capillary membrane 
gas diffusion (Magri et al., 2009). Moreover, SP-B, which differently from others SPs is produced 
only in alveolar cells, has a definite prognostic role in chronic HF (De Pasquale et al., 2004; Magri 
et al., 2015).  SP-B has also been reported to be elevated in acute pulmonary edema and to 
AC
CE
PT
ED
 M
AN
US
CR
IPT
significantly increase whenever the lung is acutely stressed as during positive pressure ventilation 
(Agostoni et al., 2011a; De Pasquale et al., 2003). At present, the correlation between SPs plasma 
levels and acute hemodynamic changes in severe HF is unknown, but there is a need to better 
understand the alveolar cell response to an hemodynamic improvement and its correlation to 
alveolar capillary membrane gas diffusion. To do so we used the inodilator Levosimendan which 
combines positive inotropic, vasodilator and cardioprotective effects, without increase of 
myocardial oxygen consumption, and it has been shown to rapidly improve symptoms and 
hemodynamics in patients with HF (Nieminen et al., 2013). Furthermore, it sustains the 
normalization of neurohormones levels (Nieminen et al., 2013). Recently we demonstrated that, on 
top of standard medical treatment, Levosimendan treatment in severe HF patients significantly 
promotes oxygen uptake at peak exercise (peak VO2) and reduces ventilation efficiency (VE/VCO2 
slope) and brain natriuretic peptide (BNP) compared to placebo, (Mushtaq et al., 2015).  
The aim of this study was therefore to evaluate whether the positive effects of Levosimendan are 
associated with a change of SPs production and whether this translates in an alveolar capillary 
membrane function improvement. 
 
METHODS 
Patients selection 
Patients who according to the European Society of Cardiology definitions (Ponikowski et al., 2016) 
had advanced (AD) HF were evaluated for the present study. Specifically, to be eligible patients had 
to have severe HF symptoms [New York Heart Association (NYHA) classes III to IV], multiple 
episodes of fluid retention and/or peripheral hypoperfusion, and objective evidence of severe 
cardiac dysfunction. Moreover, patients had also severe impairment of functional capacity, history 
of >1 HF hospitalizations in the past 6 months, and the presence of all the previous features despite 
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optimal medical therapy. All patients belonged to a cohort of chronic HF patients regularly 
followed at our institution and had experience with cardiopulmonary exercise test (CPET) in our 
laboratory.  
Patients were hospitalized because of acute hemodynamic instabilization, but, at study enrollment, 
patients were returned to a stable clinical condition (NYHA III/IV). Patients were free from both 
inotrope support and other i.v. therapies for at least 48 h prior to study inclusion, except for i.v. 
diuretics therapy. Other study inclusion criteria were: left ventricular ejection fraction at 
echocardiography ≤35%, age ≥18 years, peak VO2 ≤ 12 mL/min/kg, peak respiratory quotient 
≥1.05, and standard HF therapy. 
Exclusion criteria were: ongoing mechanical ventilation, recent or acute coronary and respiratory 
syndromes, recent sustained ventricular tachycardia/ventricular fibrillation/cardiopulmonary 
resuscitation maneuvers, severe aortic, pulmonary or mitral valve disease (or known malfunctioning 
artificial heart valve), hypertrophic cardiomyopathy, uncorrected thyroid disease, presence of any 
comorbidities which  might per se influence exercise performance. Patients with left ventricle assist 
devices as well as patients with a pacemaker-guided heart rate at rest or during exercise and patients 
in which Levosimendan was not indicated were also excluded from the present study.  
Patients’ eligibility was assessed after 48 to 72 h of clinical stabilization including medical history, 
physical examination and standard echocardiography. Afterwards a blood sample was taken for 
general chemistry including BNP, hemoglobin, creatinine levels, and blood urea nitrogen, and for 
SPs determination. Thereafter complete spirometry and CPET were performed. Levosimendan 
infusion started approximately 3 h after tests had been completed. Levosimendan (12.5 mg in 500 
mL in 5% glucose solution) was infused starting at 0.05 μg/kg/min, and progressively increased up 
to 0.2 μg/kg/min, based on patient clinical status and blood pressure, until the entire infusion had 
been administered. Notably no Levosimendan bolus was administered. Within 24 h after infusion 
completion blood samples, complete spirometry and CPET were repeated.  
AC
CE
PT
ED
 M
AN
US
CR
IPT
All patients provided written informed consent before entering the study. The protocol was 
approved by the Institutional Ethics Board (Cardiology Center Ethical Committee, N° S199/312). 
Study Procedures 
Standard spirometry and lung diffusion for carbon monoxide (DLCO) measurements were always 
performed before CPET by expert medical personnel. Forced expiratory volume in 1 s (FEV1) and 
vital capacity (FVC) were measured in triplicate and calculated according to the American Thoracic 
Society criteria (Graham et al., 2017; Miller et al., 2005) using a mass flow sensor (Sensor Medics 
2200, Sensor Medics Co., Yorba Linda, CA, USA). DLCO and its subcomponents membrane 
diffusion (DM) and capillary volume (VCap) were measured by the single-breath method (Sensor 
Medics 229D, Sensor Medics Yorba Linda, CA) by breathing gas mixtures containing three 
different O2 concentrations (21%, 40% and 60%) and 0.3% CO and 0.3% methane (CH4) as 
originally descried by Roughton and Forster (Roughton and Forster, 1957). 
DLCO was corrected for hemoglobin (Graham et al., 2017; Roughton and Forster, 1957). Prediction 
equations were derived for FEV1 and FVC from Miller et al. (Miller et al., 2005) and for DLCO 
from Graham et al. (Graham et al., 2017) and Huang et al. (Huang et al., 1994). 
CPET (Sensor Medics Vmax 29D, Sensor Medics, Yorba Linda, CA) was performed on a cyclo-
ergometer (Sensor Medics Ergo 800S, Sensor Medics, Yorba Linda, CA) using a personalized ramp 
protocol, aimed at achieving peak exercise in 10 min (Agostoni et al., 2005a), calculated on clinical 
status and previous CPET. If the exercise duration was < 7 min, the CPET was repeated the 
following day; in these cases, the blood chemistry measurements were also repeated. Expiratory O2, 
CO2, and ventilation (VE) were measured breath by breath. Peak VO2 was considered as the highest 
VO2 achieved during the exercise (mean of 20 s). Percentage of predicted peak VO2 was derived 
from Hansen and Wasserman regression equation (Wasserman et al., 2012). The VO2 vs. work-rate 
relationship was calculated throughout the entire exercise. The VE/VCO2 relationship was 
calculated as the slope of the linear relationship between VE and VCO2 from the beginning of the 
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loaded exercise to the end of the isocapnic buffering period. Oxygen pulse was calculated as 
VO2/heart rate. Exercise-induced periodic breathing was defined as a cyclic fluctuation of VE 
during exercise (Agostoni et al., 2017). Twelve-lead electrocardiograms were also continuously 
recorded (Case 800, Marquette, Milwaukee, WI, USA). Blood pressure was measured during CPET 
every 2 min, by sphygmomanometer.  
Complete spirometry and CPET were repeated after Levosimendan infusion using the same 
protocol. Medical and laboratory personal performing and interpreting pulmonary function and 
CPET were unaware of the research protocol. CPET readings were performed a posteriori by 
blinded experts.  
Specimen handling and assay 
SP-B determination was performed as previously described. Briefly, fresh blood (5 mL) was drawn 
into Vacutainer tubes containing citrate 0.129 mol/L as an anticoagulant. Plasma was immediately 
prepared by means of centrifugation at 1,500×g for 10 minutes at 4°C, divided into aliquots and 
frozen at −80°C until assayed. Plasma levels of mature SP-B were performed by an ELISA 
purchased from Uscn Life Science Inc. (Wuhan, China), with inter-assay and intra-assay coefficient 
of variation being 11.6±2.1% and 7.9±1.5%, respectively. Immature form of SP-B was performed 
by Western blotting on plasma samples, as previously described (Gargiulo et al., 2014). 
Study endpoints 
The primary endpoint was to determine the different SP-isoforms changes after Levosimendan 
infusion. The secondary endpoints were changes in BNP, DLCO, VO2 and VE/VCO2 slope after the 
treatment administrations. 
Statistical analysis 
Statistical analysis was performed using SPSS 23.0 software (SPSS Inc, Chicago, IL, USA). 
Continuous variables were expressed as means ± standard deviation or median and interquartile 
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range as appropriate, while discrete variables as absolute numbers and percentages. Comparisons 
between variables pre- and post- treatment were performed using paired t-tests for normally 
distributed variables, and Wilcoxon signed rank test for non-normally distributed variables. P < 
0.05 was considered statistically significant.  
 
 
RESULTS  
Sixty-five patients (57 males, age 70±9 years) fulfilled the study inclusion criteria, participated and 
completed the study without relevant unwanted side effects. HF etiology was ischemic heart disease 
in 40% of cases and cardiomyopathy in the remaining 60%. Standard echocardiography showed: 
left ventricle ejection fraction 25±7%, left ventricle end-diastolic volume 213±74 mL and systolic 
volume 162±66 mL and pulmonary systolic pressure 44±13 mmHg. Before Levosimendan infusion 
blood sample showed some degree of renal dysfunction and high BNP levels (Table 1). Standard 
spirometry showed below normal reduced FEV1 and FVC, 77±16 L and 80±18 L, respectively. 
DLCO was 70±17 %pred  due to a low membrane diffusion partially compensated by an increase in 
VCap (Table 1). CPET was performed in all cases but in 3 cases exercise performance was 
extremely limited and CPET judged not evaluable. Baseline peak VO2 was severely reduced as well 
as there was a decrease in peak workload, oxygen pulse and the VO2/work relationship. Conversely 
VE/VCO2 slope was high (Table 1). Periodic breathing was observed in 32 cases (54% of cases) 
with an average on the total population of loaded exercise time with periodic breathing equal to  
38%±0 Levosimendan infusion was associated with relevant BNP reduction and unchanged kidney 
function (Table 1). Furthermore a significant increase in peak VO2 was observed together with 
reduction in VE/VCO2 slope. Post Levosimendan infusion FEV1, FVC and alveolar volume 
increased while DLCO and all its components were unchanged (Table 1). In parallel all the 
measured CPET parameters improved (Table 1) and periodic breathing disappeared in 9 out of 32 
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cases. In patients with periodic breathing at baseline after infusion its lengths was reduced from 
71%±25 to 38%±33 of loaded exercise. None of the patients developed periodic breathing after 
infusion. All analyzed SPs showed significant but diverging changes after Levosimendan infusion. 
Specifically, SP-A, SP-D and the immature form of SP-B reduced while the mature form of SP-B 
increased (Table 2). 
 
 
DISCUSSION 
This study shows that Levosimendan infusion in patients with ADHF significantly improves 
exercise parameters and reduces BNP levels. This is associated with a reduction of SP-A, D and 
immature form of SP-B but with an increase of mature SP-B. Regardless DLCO was unchanged.  
The population we studied is a classical ADHF population with a very recent hemodynamic 
instabilization. In a similar population we recently showed, in a double blind placebo controlled 
study, that Levosimendan infusion is associated with relevant exercise performance improvement 
and BNP reduction (Mushtaq et al., 2015).  Therefore, we conceived the present study to assess the 
effects of these predicted hemodynamic improvement on DLCO and SPs. As in our previous report  
(Mushtaq et al., 2015), we observed with acute Levosimendan infusion a >50% reduction of BNP in 
parallel to a reduction of VE/VCO2 slope and an increase of peak VO2, oxygen pulse and VO2 work 
slope. Similarly standard spirometry measurements, as expected with a lung fluid reduction, 
improved (Agostoni et al., 2000; Guazzi et al., 1999; Puri et al., 1999). Also acute VE/VCO2 
changes are directly linked to lung fluid changes, so that a rapid rise in lung fluids is associated with 
a VE/VCO2 increase (Paolillo et al., 2013; Pellegrino et al., 2003; Robertson et al., 2004). 
Accordingly observed standard spirometry, BNP and CPET parameters changes all-together suggest 
an hemodynamic improvement and reduction of previously increased lung fluid.  However, no 
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DLCO changes were recorded albeit alveolar volume increased; the latter a datum again supportive 
of lung fluid reduction. The lack of DLCO improvement should not be considered as an unexpected 
event. As a matter of fact in a similar population we observed that ultrafiltration, a technique which 
produces a rapid lung fluid reduction, does not affect DLCO which remains unchanged despite 
pulmonary mechanics and hemodynamic amelioration both at rest and during exercise (Agostoni et 
al., 2000; Agostoni et al., 1993; Agostoni et al., 1995; Costanzo et al., 2017). Indeed in chronic HF 
the alveolar capillary membrane dysfunction is associated with interstitial fibrosis, local thrombosis 
and an increased in cellularity on top of lung fluid increase. Moreover long term treatment with 
drugs which marginally affect pulmonary hemodynamic is associated with improvement (ACE-
inhibitors and mineralcorticoid receptor antagonists) or worsening (unselective β-blockers) of 
DLCO (Agostoni et al., 2005b; Contini et al., 2013; Guazzi et al., 1997). The suggested 
mechanisms are bradikinine increase, antifibrotic action and alveolar β-2 receptor blockage for 
ACE-inhibitors, mineralocorticoid receptor antagonists blockers and unselective β-blockers, 
respectively (Agostoni et al., 2005b; Contini et al., 2013; Guazzi et al., 1997). 
SPs showed significant and apparently discordant changes after Levosimendan infusion. Reduction 
of SP-A and D, having both a widespread multiorgan production, may be linked with the well 
documented antinflammatory effect of Levosimendan (Adamopoulos et al., 2006; Yilmaz and 
Mebazaa, 2011). The reduction of the immature form of SP-B likely indicates a reduction of the 
hemodynamic stress on the alveolar capillary membrane. Indeed an acute hemodynamic and/or 
respiratory stress on the alveolar capillary membrane increases SP-B plasma level (Agostoni et al., 
2011a; Agostoni et al., 2011b; Banfi and Agostoni, 2016). The immature form of SP-B is most 
unlikely found in the blood stream. When it is found, it is a clear indicator of alveolar cell stress, 
dysfunction, if not even death. Conversely the finding of the mature form of SP-B in the blood may 
suggest a restoration of alveolar cell function with an overproduction of SP-B which reaches the 
blood stream when its intracellular catabolic process is terminated (Banfi and Agostoni, 2016). 
Clearly the present interpretation of our data is highly speculative but has relevant functional 
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meaning. Regardless it is totally unknown if a prolonged increase of SP-B mature form leads to 
DLCO improvement but, in any cases, SPs are fast responder markers of the alveolar capillary 
membrane function.   
 
This study has several limitations. The most important being that our interpretation is highly 
speculative with almost no experimental evidence. Regardless it seems to us physiologically 
convincing. Secondly, we have short term but not long term results of effects of Levosimendan or 
of prolonged hemodynamic improvement by any cause.  Indeed, multiple blood samples for SPs 
determination would have been desirable for assessing changes of SPs and DLCO with time in case 
of prolonged HF improvement. Thirdly, we do not know what the effects of possible confounders 
such as concomitant HF treatment or HF comorbidities are. Fourthly, we do not know what happens 
on the other side of the alveolar capillary membrane with the likelihood of SPs being elevated in the 
alveolar fluid of HF patients. However analyzing multiple samples of alveolar fluids was considered 
inconvenient if not unethical. Fifthly, we do not know what happens with regards to DLCO and SPs 
changes in case of acute HF without preexisting alveolar capillary damage. Finally, it must be 
recognized that Levosimendan infusion was not placebo controlled but CPET readings were 
performed a posteriori by experts in a blind fashion. 
 
In conclusion, we showed several indirect evidences of lung fluid reduction after Levosimendan 
infusion in patients with ADHF. However, DLCO remains unchanged as the likely consequence of 
its multifactorial causes, but SP-B changes of both immature and mature forms, albeit opposite, are 
a signs compatible with alveolar cell functional improvement. The effects of these changes with 
time on membrane function remain unknown.   
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Table 1: Laboratory, spirometry, DLCO and cardiopulmonary exercise test parameters before 
and after Levosimendan infusion 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                                          
 
 
 
 
 
BNP, brain natriuretic peptide; BUN, blood urea nitrogen; FEV1, forced expiratory volume in one 
second; FVC, vital capacity; VCap, Capillary volume; DLCO, lung diffusion for carbon monoxide 
adjusted for hemoglobin; DM, membrane diffusion; VA, alveolar volume. VO2, oxygen uptake; 
VE, ventilation; VCO2, CO2 productio. 
 
 
 
 
 
 
 
  
 
  
  Levosimendan   
Parameter Pre-infusion Post-infusion P- 
value 
Blood chemistry    
BNP (pg/mL) 954 (540-1736) 370 (165-874) ˂0.001 
BUN (mg/dL) 69 (56.0-94.5) 70 (49.0-98.0) 0.59 
Creatinine (mg/dL) 1.46 (1.16-1.80) 1.40 (1.09-1.93) 
 
0.12 
Spirometry    
FEV1 (L) 2.09±0.56 2.26±063 ˂0.001 
FVC (L) 2.87±0.74 3.09±0.83 ˂0.001 
DLCO (mL/mmHg/min) 18.3±4.5 17.9±4.1 0.17 
VCap (L) 114 (85-177) 120 (104-171) 0.79 
DM (mL/min/mmHg) 24±9 22±6 0.07 
VA (L) 4.67±1.18 4.84±1.17 0.01 
Cardiopulmonary exercise test     
Peak VO2 (L/min) 0.74±0.23 0.84±0.22 <0.001 
Peak VO2 (mL/Kg/min) 10.1±2.36 11.50±2.30 <0.001 
Peak VO2 (% pred) 44±12.40 50±1.09 <0.001 
Peak workload (watt) 42 (32-57) 49 (39-61) <0.001 
Peak O2 pulse (mL/beat) 8.2±2.64 8.80±2.65 0.002 
VO2/workload slope (mL/min/W) 9.0±1.9 9.6±1.5 0.001 
VE/VCO2 slope  41±10 36±7 <0.001 
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Table 2: Pulmonary Surfactant proteins (SPs)  levels before and after Levosimendan infusion 
 
 
 
 
 
 
SP, Surfactant Protein; AU, arbitrary unit 
 
 
 
  Levosimendan   
Parameter Pre-infusion Post-infusion P- value 
SP-A (ng/mL) 73.7±25.3 66.3±22.7 ˂0.001 
SP-D (ng/mL) 247±121 223±110 <0.001 
SP-B immature (AU) 39.4±18.7 34.4±17.9 ˂0.001 
SP-B mature (ng/mL) 424±218 461±243 <0.001 
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